Press Releases

Press Releases

Date Title  
Mar 19, 2013
Prothena Announces Appointment of Biotech Pioneer to Board of Directors
DUBLIN, Ireland, March 19, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq: PRTA ), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Christopher S.
Feb 27, 2013
Prothena Achieves Orphan Drug Status in EU for Lead Program NEOD001
Potential Treatment for Systemic Amyloidoses Also Has US Designation
Feb 13, 2013
Prothena to Ring NASDAQ Stock Market Opening Bell
DUBLIN, Ireland, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that its President and Chief Executive Officer,
Jan 07, 2013
Prothena Announces Addition of Industry Veterans to Board of Directors
Richard T. Collier and Shane Cooke Join Board of Directors
Dec 21, 2012
Prothena Begins Trading on NASDAQ Global Market Under Symbol "PRTA"
Company Completes Successful Separation and Share Distribution From Elan
Nov 13, 2012
Prothena to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Prothena to Present at the Lazard Capital Markets 9th Annual Healthcare Conference South San Francisco, CA, November 13, 2012 – Prothena Corporation, a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today
Aug 13, 2012
Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders
Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders Creates two independent, unique companies Transaction aligns assets, timelines, and risk/reward Elan to become immediately profitable and a high growth company Targeting $1.00 earnings per share by 2015 with